208 related articles for article (PubMed ID: 21292366)
21. Risk of incident ESRD: a comprehensive look at cardiovascular risk factors and 17 years of follow-up in the Atherosclerosis Risk in Communities (ARIC) Study.
Bash LD; Astor BC; Coresh J
Am J Kidney Dis; 2010 Jan; 55(1):31-41. PubMed ID: 19932544
[TBL] [Abstract][Full Text] [Related]
22. Effects of antiproteinuric intervention on elevated connective tissue growth factor (CTGF/CCN-2) plasma and urine levels in nondiabetic nephropathy.
Slagman MC; Nguyen TQ; Waanders F; Vogt L; Hemmelder MH; Laverman GD; Goldschmeding R; Navis G
Clin J Am Soc Nephrol; 2011 Aug; 6(8):1845-50. PubMed ID: 21784839
[TBL] [Abstract][Full Text] [Related]
23. Effect of GFR on plasma N-terminal connective tissue growth factor (CTGF) concentrations.
Gerritsen KG; Abrahams AC; Peters HP; Nguyen TQ; Koeners MP; den Hoedt CH; Dendooven A; van den Dorpel MA; Blankestijn PJ; Wetzels JF; Joles JA; Goldschmeding R; Kok RJ
Am J Kidney Dis; 2012 May; 59(5):619-27. PubMed ID: 22342213
[TBL] [Abstract][Full Text] [Related]
24. Kidney Damage Biomarkers and Incident Chronic Kidney Disease During Blood Pressure Reduction: A Case-Control Study.
Zhang WR; Craven TE; Malhotra R; Cheung AK; Chonchol M; Drawz P; Sarnak MJ; Parikh CR; Shlipak MG; Ix JH;
Ann Intern Med; 2018 Nov; 169(9):610-618. PubMed ID: 30357395
[TBL] [Abstract][Full Text] [Related]
25. Urinary epidermal growth factor as a prognostic marker for the progression of Alport syndrome in children.
Li B; Zhang Y; Wang F; Nair V; Ding F; Xiao H; Yao Y; Kretzler M; Ju W; Ding J
Pediatr Nephrol; 2018 Oct; 33(10):1731-1739. PubMed ID: 29948307
[TBL] [Abstract][Full Text] [Related]
26. Metabolic syndrome and the development of CKD in American Indians: the Strong Heart Study.
Lucove J; Vupputuri S; Heiss G; North K; Russell M
Am J Kidney Dis; 2008 Jan; 51(1):21-8. PubMed ID: 18155529
[TBL] [Abstract][Full Text] [Related]
27. Bidirectional association of retinal vessel diameters and estimated GFR decline: the Beaver Dam CKD Study.
Sabanayagam C; Shankar A; Klein BE; Lee KE; Muntner P; Nieto FJ; Tsai MY; Cruickshanks KJ; Schubert CR; Brazy PC; Coresh J; Klein R
Am J Kidney Dis; 2011 May; 57(5):682-91. PubMed ID: 21439697
[TBL] [Abstract][Full Text] [Related]
28. Urinary Biomarkers and Risk of ESRD in the Atherosclerosis Risk in Communities Study.
Foster MC; Coresh J; Bonventre JV; Sabbisetti VS; Waikar SS; Mifflin TE; Nelson RG; Grams M; Feldman HI; Vasan RS; Kimmel PL; Hsu CY; Liu KD;
Clin J Am Soc Nephrol; 2015 Nov; 10(11):1956-63. PubMed ID: 26350438
[TBL] [Abstract][Full Text] [Related]
29. Serum phosphorus predicts incident chronic kidney disease and end-stage renal disease.
O'Seaghdha CM; Hwang SJ; Muntner P; Melamed ML; Fox CS
Nephrol Dial Transplant; 2011 Sep; 26(9):2885-90. PubMed ID: 21292817
[TBL] [Abstract][Full Text] [Related]
30. Change in novel filtration markers and risk of ESRD.
Rebholz CM; Grams ME; Matsushita K; Selvin E; Coresh J
Am J Kidney Dis; 2015 Jul; 66(1):47-54. PubMed ID: 25542414
[TBL] [Abstract][Full Text] [Related]
31. Metabolomic Markers of Kidney Function Decline in Patients With Diabetes: Evidence From the Chronic Renal Insufficiency Cohort (CRIC) Study.
Kwan B; Fuhrer T; Zhang J; Darshi M; Van Espen B; Montemayor D; de Boer IH; Dobre M; Hsu CY; Kelly TN; Raj DS; Rao PS; Saraf SL; Scialla J; Waikar SS; Sharma K; Natarajan L;
Am J Kidney Dis; 2020 Oct; 76(4):511-520. PubMed ID: 32387023
[TBL] [Abstract][Full Text] [Related]
32. Reduction of urinary connective tissue growth factor by Losartan in type 1 patients with diabetic nephropathy.
Andersen S; van Nieuwenhoven FA; Tarnow L; Rossing P; Rossing K; Wieten L; Goldschmeding R; Parving HH
Kidney Int; 2005 Jun; 67(6):2325-9. PubMed ID: 15882275
[TBL] [Abstract][Full Text] [Related]
33. NT-proBNP and troponin T and risk of rapid kidney function decline and incident CKD in elderly adults.
Bansal N; Katz R; Dalrymple L; de Boer I; DeFilippi C; Kestenbaum B; Park M; Sarnak M; Seliger S; Shlipak M
Clin J Am Soc Nephrol; 2015 Feb; 10(2):205-14. PubMed ID: 25605700
[TBL] [Abstract][Full Text] [Related]
34. A multi-marker approach to predict incident CKD and microalbuminuria.
Fox CS; Gona P; Larson MG; Selhub J; Tofler G; Hwang SJ; Meigs JB; Levy D; Wang TJ; Jacques PF; Benjamin EJ; Vasan RS
J Am Soc Nephrol; 2010 Dec; 21(12):2143-9. PubMed ID: 20966127
[TBL] [Abstract][Full Text] [Related]
35. Retinal arteriolar narrowing and subsequent development of CKD Stage 3: the Multi-Ethnic Study of Atherosclerosis (MESA).
Yau JW; Xie J; Kawasaki R; Kramer H; Shlipak M; Klein R; Klein B; Cotch MF; Wong TY
Am J Kidney Dis; 2011 Jul; 58(1):39-46. PubMed ID: 21549464
[TBL] [Abstract][Full Text] [Related]
36. Effects of Intensive Blood Pressure Lowering on Kidney Tubule Injury in CKD: A Longitudinal Subgroup Analysis in SPRINT.
Malhotra R; Craven T; Ambrosius WT; Killeen AA; Haley WE; Cheung AK; Chonchol M; Sarnak M; Parikh CR; Shlipak MG; Ix JH;
Am J Kidney Dis; 2019 Jan; 73(1):21-30. PubMed ID: 30291012
[TBL] [Abstract][Full Text] [Related]
37. Thyroid hormones associate with risk of incident chronic kidney disease and rapid decline in renal function: a prospective investigation.
Huang X; Ding L; Peng K; Lin L; Wang T; Zhao Z; Xu Y; Lu J; Chen Y; Wang W; Bi Y; Ning G; Xu M
J Transl Med; 2016 Dec; 14(1):336. PubMed ID: 27914474
[TBL] [Abstract][Full Text] [Related]
38. Urine biomarkers of tubular injury do not improve on the clinical model predicting chronic kidney disease progression.
Hsu CY; Xie D; Waikar SS; Bonventre JV; Zhang X; Sabbisetti V; Mifflin TE; Coresh J; Diamantidis CJ; He J; Lora CM; Miller ER; Nelson RG; Ojo AO; Rahman M; Schelling JR; Wilson FP; Kimmel PL; Feldman HI; Vasan RS; Liu KD; ;
Kidney Int; 2017 Jan; 91(1):196-203. PubMed ID: 28029431
[TBL] [Abstract][Full Text] [Related]
39. Kidney function and risk of peripheral arterial disease: results from the Atherosclerosis Risk in Communities (ARIC) Study.
Wattanakit K; Folsom AR; Selvin E; Coresh J; Hirsch AT; Weatherley BD
J Am Soc Nephrol; 2007 Feb; 18(2):629-36. PubMed ID: 17215445
[TBL] [Abstract][Full Text] [Related]
40. Plasma connective tissue growth factor is an independent predictor of end-stage renal disease and mortality in type 1 diabetic nephropathy.
Nguyen TQ; Tarnow L; Jorsal A; Oliver N; Roestenberg P; Ito Y; Parving HH; Rossing P; van Nieuwenhoven FA; Goldschmeding R
Diabetes Care; 2008 Jun; 31(6):1177-82. PubMed ID: 18344285
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
